Falciparum malaria Infections and Infestations Falciparum malaria
Conditions
Interventions
Comparison of two different treatment regimes: dihydroartemisinin-piperaquine and mefloquine-artesunate. Both treatment regimes were given observed or not observed
total of four study groups.
Sponsors
Doctors Without Borders (Medecins sans Frontieres [MSF]) (The Netherlands)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with fever (axillary temperature >37.5°C), or a history of fever within 48 hours 2. Confirmed falciparum malaria (mixed infection P. falciparum with P. vivax and/or P. malariae were included), with more than 500 but less than 100,000 asexual parasites per ml
Exclusion criteria
Exclusion criteria: 1. Signs of severe and complicated malaria 2. Children below one-year-old 3. Pregnant women 4. Patients with a history of taking mefloquine during the previous two months 5. Patients taken any other antimalarial drugs in the previous 48 hours 6. Patients with a history of psychiatric diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Polymerase chain reaction (PCR) adjusted parasitological failure rates by day 42 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Vivax appearances 2. Gametocytaemia (person gametocyte weeks between day 0 and 42) 3. Whole blood piperaquine levels at day 7 4. Adverse effects | — |
Countries
Myanmar
Outcome results
None listed